Treatment persistence and switching patterns of ABP 501 in European patients with inflammatory bowel disease.

"R. Jin, G. Kricorian, and J. L. O’Kelly are employees and stockholders of Amgen. S. Kruppert, F. Scholz, I. Bardoulat, and K. Karzazi are employees of IQVIA Real World Solutions. W. Reinishch has received research grants from Takeda, AbbVie, Pfizer, Janssen, consulting fees from AbbVie, AOP Orphan, Bioclinica, Bristol Myers Squibb, Calyx, Eli Lilly, Galapagos, Gilead, Index Pharma, Janssen, Landos Biopharma, Microbiotica, MSD, Pfizer, Protagonist, Seres Therapeutics, Takeda, Teva Pharma, and speakers bureau fees from AbbVie, Celltrion, Janssen, Galapagos, MSD, Takeda."

"Funding: The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This study was funded by Amgen Inc., Thousand Oaks, CA, USA."